Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.02.11.579865

Oncogenic STIL-mediated loss of BRCA1 functionality causes DNA damage and centrosome amplification

Abstract

DNA damages increase centrosome number, a typical phenotype in many cancers. However, the molecular linkers between the two pathways remain elusive. STIL (SCL/TAL1 Interrupting locus) is a core centrosome-organizing protein overexpressed in different cancer types. This work shows that STIL forms a complex with the DNA damage response protein, BRCA1, and is required for regulating its protein stability. Subsequently, STIL depletion resulting in BRCA1 loss from the nucleus causes centrosome amplification and DNA damage. We also identified a heterozygous missense mutation (S76L) in STIL from the pan-cancer datasets, which does not affect total BRCA1 protein levels. However, it reduces BRCA1 nuclear localization with enhanced centrosome recruitment simultaneously at the S-phase. The enhanced BRCA1 at centrosome causes an increase in Aurora-A kinase levels at centrosomes, thus culminating in DNA damage and centrosome amplification. The expression of exogenous BRCA1 can push back this imbalance of the STIL-BRCA1 axis in oncogenic conditions. The amplified centrosomes in oncogenic STIL condition cluster in the M phase and cause pseudo-bipolar spindle organization. We could decluster them by the HSET(KIFC1)-specific inhibitor, CW069, suggesting a promising target for anti-cancer treatment.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sanghi, S., Singh, P.. 2024-02-12. Oncogenic STIL-mediated loss of BRCA1 functionality causes DNA damage and centrosome amplification. https://doi.org/10.1101/2024.02.11.579865

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sequence context and partner availability specify divergent cell fates from a single transcription factor

Transcription factors drive the gene regulatory networks that control developmental transitions, yet which of their many targets a cell uses remains unresolved. Expressing Cebp, Cebp{beta} or Cebp{delta} identically, alone or with Oct4, Sox2, Klf4 and cMyc, gave four outcomes: adipocyte from fibroblasts and neural stem cells, trophectoderm from embryonic stem cells, and myeloid from B cells. Raising Cebp levels changed how many sites it reached, not which sequence it read: clustered motifs maintained somatic enhancers, while spillover onto low-copy sites created de novo enhancers carrying composites of Cebp and cell-type-restricted partners. In fibroblasts, Cebp also redistributed Oct4, Sox2 and Klf4 from early targets, blocking iPSC formation. Supplying the predicted partners rewrote the output: Spi1 redirected Cebp into parallel adipogenic and myeloid programs, via a transient PpargCD45 state using separate enhancers for each; TFAP2C abolished adipogenic conversion. Motif density and partner composites therefore assemble a factor's instructive output in the receiving cell.

cell biology↗

Tracking the conformational dynamics of single molecules in live cells; GTPase cycling in Cdc42 gradients and microclusters

The Rho family of GTPases play a critical role in many cellular processes by acting as molecular switches relying on conformational changes to transition between active and inactive states. The spatial distribution and kinetics of these conformational changes are complex and vary across the cell. We describe here biosensors based on environment-responsive fluorescent dyes, capable of reporting the conformational changes of individual GTPase molecules as they traffic within living cells (SPARC Cdc42 and SPARC Rac1, 'Single Particle Activation Reporter Constructs'). We use SPARC Cdc42 to determine the rates of different steps in GTPase regulation, activation/inactivation and membrane insertion, that together generate localized gradients of Cdc42 activity driving cell motility. The biosensors also revealed heterogeneously distributed clusters of Cdc42, the mechanisms of their activation, and potential roles in polarized motility.

cell biology↗

High-content screening identifies FDA-approved activators of mitophagy

Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.

cell biology↗